Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00330850
Other study ID # PRO-513301
Secondary ID
Status Completed
Phase Phase 3
First received May 26, 2006
Last updated March 30, 2007
Start date May 2006
Est. completion date December 2006

Study information

Verified date March 2007
Source ProEthic Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the study is to show the efficacy of a single dose of PRO-513 for treating subjects suffering moderate pain form a migraine attack, with or without aura. The study is also intended to show the effectiveness of PRO-513 for associated symptoms of nausea, photophobia, and phonophobia due to a migraine attack.


Recruitment information / eligibility

Status Completed
Enrollment 650
Est. completion date December 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male and Female subjects

- 18-65 years of age

- Primary diagnosis of migraine attack with aura or migraine attack without aura

- Migraine history of averaging at least 1 migraine attack per month but averaging not more than 6 migraine attacks per month over the prior year

- Female subjects must use an effective form of birth control

- Listing of additional inclusion criteria are available through the Sponsor

Exclusion Criteria:

- Excluding subjects with a history of other serious events causing secondary headaches

- Excluding subjects with a current medical condition that could interfere with the overall study intent or affect the absorption, distribution, metabolism, or excretion of the study medication

- Excluding subjects with a history or current medical condition that could confound the study results or use of a concomitant medication that could interfere with the study drug

- Listing of additional exclusion criteria are available through the Sponsor

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
PRO-513


Locations

Country Name City State
United States The Innovative Clinical Research Center Alexandria Virginia
United States Michigan Head-Pain and Neurologic Institute Ann Arbor Michigan
United States DermResearch, Inc. Austin Texas
United States J&S Studies, Inc. Bryan Texas
United States Diamond Headache Clinic Chicago Illinois
United States Associated Neurologists of Southern CT Fairfield Connecticut
United States LCFP Inc. Ft. Myers Florida
United States Headache Wellness Center Greensboro North Carolina
United States Houston Headache Clinic Houston Texas
United States Advanced Healthcare, S.C. Milwaukee Wisconsin
United States New York Headache Center New York New York
United States Palm Beach Neurological Center Palm Beach Gardens Florida
United States Road Runner Research, Ltd. San Antonio Texas
United States Mercy Health Research St. Louis Missouri
United States New England Center for Headache Stamford Connecticut
United States International Research Center Towson Maryland

Sponsors (1)

Lead Sponsor Collaborator
ProEthic Pharmaceuticals

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A